Analysts See $-0.13 EPS for OrthoPediatrics Corp. (KIDS)

July 14, 2018 - By Lisa Delgado

Analysts expect OrthoPediatrics Corp. (NASDAQ:KIDS) to report $-0.13 EPS on August, 13.After having $-0.41 EPS previously, OrthoPediatrics Corp.’s analysts see -68.29 % EPS growth. It closed at $29.37 lastly. It is down 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

OrthoPediatrics Corp. designs, develops, and sells orthopedic implants for children. The company has market cap of $375.12 million. It offers trauma and deformity correction products, including cannulated screws; The Locking Cannulated Blade plate system that offers various treatment options for pediatric hip deformity, fixed knee flexion deformity, and trauma; The Locking Proximal Femur plate system for long bone fractures and osteotomies in children and adolescents; flexible nailing systems; The OP PediFrag System, a fragment set for pediatric orthopedic surgery; The PediLoc Extension Osteotomy plates; locking plated systems for the treatment of pediatric femur fractures and osteotomies; intramedullary nails; plate systems that provide physeal tethering techniques; and an engineered device for casting procedures. It currently has negative earnings. The firm also offers spine and sports medicine systems, and clinical education.

More important recent OrthoPediatrics Corp. (NASDAQ:KIDS) news were published by: which released: “OrthoPediatrics Corp. Announces First RESPONSE Spine Surgery Performed in Japan” on June 18, 2018, also published article titled: “OrthoPediatrics Corp. Announces Full Launch of Pediatric Nailing Platform | FEMUR”, published: “OrthoPediatrics Corp. (KIDS) PT Raised to $30 at Piper Jaffray Following Investor Meetings” on July 05, 2018. More interesting news about OrthoPediatrics Corp. (NASDAQ:KIDS) was released by: and their article: “OrthoPediatrics Corp. Announces First RESPONSE Spine Surgery” with publication date: June 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.